These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

444 related articles for article (PubMed ID: 28248126)

  • 21. Magnetic Resonance Spectroscopic Assessment of Isocitrate Dehydrogenase Status in Gliomas: The New Frontiers of Spectrobiopsy in Neurodiagnostics.
    Di Ieva A; Magnussen JS; McIntosh J; Mulcahy MJ; Pardey M; Choi C
    World Neurosurg; 2020 Jan; 133():e421-e427. PubMed ID: 31526886
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas.
    Choi C; Ganji SK; DeBerardinis RJ; Hatanpaa KJ; Rakheja D; Kovacs Z; Yang XL; Mashimo T; Raisanen JM; Marin-Valencia I; Pascual JM; Madden CJ; Mickey BE; Malloy CR; Bachoo RM; Maher EA
    Nat Med; 2012 Jan; 18(4):624-9. PubMed ID: 22281806
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Selective Detection of the D-enantiomer of 2-Hydroxyglutarate in the CSF of Glioma Patients with Mutated Isocitrate Dehydrogenase.
    Kalinina J; Ahn J; Devi NS; Wang L; Li Y; Olson JJ; Glantz M; Smith T; Kim EL; Giese A; Jensen RL; Chen CC; Carter BS; Mao H; He M; Van Meir EG
    Clin Cancer Res; 2016 Dec; 22(24):6256-6265. PubMed ID: 27340277
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Volumetric relationship between 2-hydroxyglutarate and FLAIR hyperintensity has potential implications for radiotherapy planning of mutant IDH glioma patients.
    Jafari-Khouzani K; Loebel F; Bogner W; Rapalino O; Gonzalez GR; Gerstner E; Chi AS; Batchelor TT; Rosen BR; Unkelbach J; Shih HA; Cahill DP; Andronesi OC
    Neuro Oncol; 2016 Nov; 18(11):1569-1578. PubMed ID: 27382115
    [TBL] [Abstract][Full Text] [Related]  

  • 25. IDH1 p.R132H ctDNA and D-2-hydroxyglutarate as CSF biomarkers in patients with IDH-mutant gliomas.
    Fujita Y; Nunez-Rubiano L; Dono A; Bellman A; Shah M; Rodriguez JC; Putluri V; Kamal AHM; Putluri N; Riascos RF; Zhu JJ; Esquenazi Y; Ballester LY
    J Neurooncol; 2022 Sep; 159(2):261-270. PubMed ID: 35816267
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy.
    Andronesi OC; Kim GS; Gerstner E; Batchelor T; Tzika AA; Fantin VR; Vander Heiden MG; Sorensen AG
    Sci Transl Med; 2012 Jan; 4(116):116ra4. PubMed ID: 22238332
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Detection of oncogenic IDH1 mutations using magnetic resonance spectroscopy of 2-hydroxyglutarate.
    Andronesi OC; Rapalino O; Gerstner E; Chi A; Batchelor TT; Cahill DP; Sorensen AG; Rosen BR
    J Clin Invest; 2013 Sep; 123(9):3659-63. PubMed ID: 23999439
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tissue 2-Hydroxyglutarate and Preoperative Seizures in Patients With Diffuse Gliomas.
    Ohno M; Hayashi Y; Aikawa H; Hayashi M; Miyakita Y; Takahashi M; Matsushita Y; Yoshida A; Satomi K; Ichimura K; Hamada A; Narita Y
    Neurology; 2021 Nov; 97(21):e2114-e2123. PubMed ID: 34610989
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Accuracy of 2-hydroxyglutarate quantification by short-echo proton-MRS at 3 T: a phantom study.
    Bertolino N; Marchionni C; Ghielmetti F; Burns B; Finocchiaro G; Anghileri E; Bruzzone MG; Minati L
    Phys Med; 2014 Sep; 30(6):702-7. PubMed ID: 24685182
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A comparative study of short- and long-TE ¹H MRS at 3 T for in vivo detection of 2-hydroxyglutarate in brain tumors.
    Choi C; Ganji S; Hulsey K; Madan A; Kovacs Z; Dimitrov I; Zhang S; Pichumani K; Mendelsohn D; Mickey B; Malloy C; Bachoo R; Deberardinis R; Maher E
    NMR Biomed; 2013 Oct; 26(10):1242-50. PubMed ID: 23592268
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy.
    Pope WB; Prins RM; Albert Thomas M; Nagarajan R; Yen KE; Bittinger MA; Salamon N; Chou AP; Yong WH; Soto H; Wilson N; Driggers E; Jang HG; Su SM; Schenkein DP; Lai A; Cloughesy TF; Kornblum HI; Wu H; Fantin VR; Liau LM
    J Neurooncol; 2012 Mar; 107(1):197-205. PubMed ID: 22015945
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MR spectroscopy for in vivo assessment of the oncometabolite 2-hydroxyglutarate and its effects on cellular metabolism in human brain gliomas at 9.4T.
    Bisdas S; Chadzynski GL; Braun C; Schittenhelm J; Skardelly M; Hagberg GE; Ethofer T; Pohmann R; Shajan G; Engelmann J; Tabatabai G; Ziemann U; Ernemann U; Scheffler K
    J Magn Reson Imaging; 2016 Oct; 44(4):823-33. PubMed ID: 26970248
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Detection of "oncometabolite" 2-hydroxyglutarate by magnetic resonance analysis as a biomarker of IDH1/2 mutations in glioma.
    Kalinina J; Carroll A; Wang L; Yu Q; Mancheno DE; Wu S; Liu F; Ahn J; He M; Mao H; Van Meir EG
    J Mol Med (Berl); 2012 Oct; 90(10):1161-1171. PubMed ID: 22426639
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Glycine by MR spectroscopy is an imaging biomarker of glioma aggressiveness.
    Tiwari V; Daoud EV; Hatanpaa KJ; Gao A; Zhang S; An Z; Ganji SK; Raisanen JM; Lewis CM; Askari P; Baxter J; Levy M; Dimitrov I; Thomas BP; Pinho MC; Madden CJ; Pan E; Patel TR; DeBerardinis RJ; Sherry AD; Mickey BE; Malloy CR; Maher EA; Choi C
    Neuro Oncol; 2020 Jul; 22(7):1018-1029. PubMed ID: 32055850
    [TBL] [Abstract][Full Text] [Related]  

  • 35. On the Utility of Short Echo Time (TE) Single Voxel 1H-MRS in Non-Invasive Detection of 2-Hydroxyglutarate (2HG); Challenges and Potential Improvement Illustrated with Animal Models Using MRUI and LCModel.
    Heo H; Kim S; Lee HH; Cho HR; Xu WJ; Lee SH; Park CK; Park S; Choi SH; Kim H
    PLoS One; 2016; 11(1):e0147794. PubMed ID: 26820720
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vivo Metabolic Profiles as Determined by
    Wenger KJ; Hattingen E; Franz K; Steinbach J; Bähr O; Pilatus U
    Clin Neuroradiol; 2019 Mar; 29(1):27-36. PubMed ID: 28983683
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rapid detection of 2-hydroxyglutarate in frozen sections of IDH mutant tumors by MALDI-TOF mass spectrometry.
    Longuespée R; Wefers AK; De Vita E; Miller AK; Reuss DE; Wick W; Herold-Mende C; Kriegsmann M; Schirmacher P; von Deimling A; Pusch S
    Acta Neuropathol Commun; 2018 Mar; 6(1):21. PubMed ID: 29499756
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Isocitrate dehydrogenase mutation as a therapeutic target in gliomas.
    Han CH; Batchelor TT
    Chin Clin Oncol; 2017 Jun; 6(3):33. PubMed ID: 28705010
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cystathionine as a marker for 1p/19q codeleted gliomas by in vivo magnetic resonance spectroscopy.
    Branzoli F; Pontoizeau C; Tchara L; Di Stefano AL; Kamoun A; Deelchand DK; Valabrègue R; Lehéricy S; Sanson M; Ottolenghi C; Marjańska M
    Neuro Oncol; 2019 Jun; 21(6):765-774. PubMed ID: 30726924
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 2-Hydroxyglutarate concentration in serum from patients with gliomas does not correlate with IDH1/2 mutation status or tumor size.
    Capper D; Simon M; Langhans CD; Okun JG; Tonn JC; Weller M; von Deimling A; Hartmann C;
    Int J Cancer; 2012 Aug; 131(3):766-8. PubMed ID: 21913188
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.